jens juul holst glp 1 of the Novo Nordisk Foundation Center for Basic Metabolic Research and the University of Copenhagen was awarded the 2025 Breakthrough Prize in Life Sciences for his discovery and Jens Juul Holst: physician-scientist and

Larger randomized controlled trials with clinical endpoints, focusing on both cardiovascular morbidity and mortality, should be performed to verify the cardioprotective properties of GLP-1R agonists in patients with CAD and select the population in whom it will be most effective

In: StanleyCADe LeonDD, editors

The ketogenic diet, by eliminating carbohydrates, dramatically reduces the insulin demand on the pancreas

doi:10.1016/j.eclinm.2021.101213

These effects were substantial and help elucidate the remarkable glucose homeostasis abilities of tirzepatide observed in SURPASS-2 trial when compared with semaglutide (112)

Furthermore, in patients with NASH, GLP-1 decreases de novo lipogenesis and reduces levels of lipolysis-induced FFA and triglyceride-derived toxic metabolites (45)